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Background: Growth-differentiation factor-15 (GDF-15) has been associated with future cardiovascular (CV) events in patients with acute coronary 
syndrome or heart failure but its association with CV events in patients with stable ischemic heart disease is less clear.
Methods: We measured serum GDF-15 and cardiac disease severity in 981 patients with stable ischemic heart disease who were recruited for the 
Heart and Soul Study between September 2000 and December 2002. Subsequent CV events (myocardial infarction, heart failure hospitalization, or 
death) were determined by chart review.
Results: There were 116 MIs, 164 HF hospitalizations, and 359 deaths. Each doubling in GDF-15 was associated with an increased risk of CV 
events (HR 2.72, 95% CI 2.30-3.21; p<0.0001). This association persisted after adjustment for covariates including comorbid conditions, measures 
of cardiac disease severity, inflammatory markers, NT-proBNP, and adipokines (HR 1.72, 95% CI 1.26-2.35; p<0.001). The association was 
significant for each of the individual events (MI, HF and death). Compared with participants who had GDF-15 levels in the lowest tertile, those with 
GDF-15 levels in the highest tertile were more likely to have a CV event (HR 2.09, 95% CI 1.22-3.60, p=0.008 adjusted for all covariates).
Conclusions: Higher levels of GDF-15 predict major CV events including MI, HF, and death in patients with stable ischemic heart disease 
suggesting GDF-15 is capturing an element of risk not explained by other known risk factors.
